<DOC>
	<DOCNO>NCT02606877</DOCNO>
	<brief_summary>The primary objective study investigate effect steady state pirfenidone pharmacokinetics nintedanib metabolite follow oral administration 2403 mg/day pirfenidone investigate effect steady state nintedanib pharmacokinetics pirfenidone steady state follow oral administration 150 mg bid nintedanib . There two cohort patient ; first one consist patient treat pirfenidone nintedanib , second one consist patient pirfenidone treatment .</brief_summary>
	<brief_title>A Study Compare Amount Nintedanib Pirfenidone Blood When Nintedanib Pirfenidone Are Given Separately Combination</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Inclusion criterion : Any patient diagnose IPF comply eligibility requirement may qualify participation trial . Written inform consent consistent ICHGCP local law , sign prior study procedure perform ( include require washout ) . Male female patient age &gt; =40 year Visit 1 IPF diagnosis , base upon ATS/ERS/JRS/ALAT 2011 guideline chest highresolution compute tomography ( HRCT ) scan . FVC &gt; =50 % predict normal Visit 1 DLCO ( correct Hb [ visit 1 ] ) : 30 % 79 % predict normal visit 2 . ( test perform visit 1 2 , screen period ) Currently treat pirfenidone full dose ( patient go Group 2 ) . Exclusion criterion : ALT , AST &gt; 1.5 fold upper limit normal ( ULN ) visit 1 . Total bilirubin &gt; 1.5 fold ULN visit 1 . Underlying chronic liver disease ( Child Pugh A , B , C hepatic impairment ) Relevant airways obstruction ( i.e . prebronchodilator FEV1/FVC &lt; 0.7 visit 1 ) . History myocardial infarction within 6 month visit 1 unstable angina within 1 month visit 1 . Bleeding Risk : Known genetic predisposition bleeding Patients require fibrinolysis , fulldose therapeutic anticoagulation ( e.g . vitamin K antagonist , dabigatran , heparin , hirudin , etc . ) high dose antiplatelet therapy . History haemorrhagic central nervous system ( CNS ) event within 12 month prior visit 1 . History haemoptysis haematuria , active gastrointestinal bleeding ulcer and/or major injury surgery within 3 month prior visit 1. International normalise ratio ( INR ) &gt; 2 visit 1 . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 150 % institutional ULN visit 1 . Planned major surgery trial participation , include lung transplantation , major abdominal major intestinal surgery . History thrombotic event ( include stroke transient ischemic attack ) within 12 month visit 1 . Severe renal impairment ( Creatinine clearance &lt; 30 mL/min calculate CockcroftGault formula visit 1 ) endstage renal disease require dialysis . Treatment nacetylcysteine , prednisone &gt; 15 mg daily &gt; 30 mg every 2 day OR equivalent dose oral corticosteroid fluvoxamine within 2 week visit 2 . Treatment azathioprine , cyclophosphamide , cyclosporine well investigational drug within 8 week visit 2 . Previous treatment pirfenidone past three month prior Visit 2 ( Group 1 ) . Previous treatment nintedanib past 14 day prior Visit 2 . Permanent discontinuation nintedanib pirfenidone past due adverse event consider drugrelated . Known hypersensitivity nintedanib , pirfenidone excipients ; peanut soya . A disease condition opinion investigator may interfere test procedure put patient risk participate trial . Alcohol drug abuse , opinion treat physician would interfere treatment . Women pregnant , nursing , plan become pregnant trial . Women childbearing potential use highly effective method birth control per ICH M3 , note 3 , highly effective method birth control define , alone combination , result low failure rate le 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomise partner . Barrier contraceptive ( e.g . male condom diaphragm ) acceptable use combination spermicide ( e.g . foam , gel ) . Contraception must use 28 day prior 3 month nintedanib pirfenidone administration . Patients able understand follow study procedure include completion diary without help . Current smoker ( vaping ecigarettes acceptable )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>